Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001390790 | SCV001592636 | pathogenic | not provided | 2023-02-23 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (gnomAD no frequency). For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 1076787). This variant has not been reported in the literature in individuals affected with MSH3-related conditions. This sequence change creates a premature translational stop signal (p.Gln664Hisfs*10) in the MSH3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH3 are known to be pathogenic (PMID: 27476653). |
Ambry Genetics | RCV002420868 | SCV002718249 | pathogenic | Hereditary cancer-predisposing syndrome | 2019-10-02 | criteria provided, single submitter | clinical testing | The c.1992delG pathogenic mutation, located in coding exon 14 of the MSH3 gene, results from a deletion of one nucleotide at nucleotide position 1992, causing a translational frameshift with a predicted alternate stop codon (p.Q664Hfs*10). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Myriad Genetics, |
RCV003458700 | SCV004189226 | pathogenic | Familial adenomatous polyposis 4 | 2023-08-30 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. |